Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis.

Mackenzie L Cottrell,Heather M A Prince,Amanda P Schauer,Craig Sykes,Kaitlyn Maffuid,Amanda Poliseno,Tae-Wook Chun,Erin Huiting,Frank Z Stanczyk,Anne F Peery,Evan S Dellon,Jessica L Adams,Cindy Gay,Angela D M Kashuba

CLINICAL INFECTIOUS DISEASES（2019）

引用 31|浏览25

暂无评分

摘要

Feminizing hormone therapy (FHT) may interact with human immunodeficiency virus preexposure prophylaxis (PrEP). We found that transgender women who took FHT exhibited a 7-fold lower rectal tissue ratio of PrEP's active metabolites vs competing deoxynucleotides compared to cisgender women and men (P = .03) that inversely correlated with estradiol (ρ = -0.79; P < .05). Thus, FHT may negatively impact PrEP efficacy. Clinical Trials Registration . NCT02983110.

查看译文

关键词

transgender,preexposure prophylaxis,lower gastrointestinal tract,HIV,feminizing hormone therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要